Literature DB >> 20334534

Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.

Takahiro Akaishi1, Hiroaki Kurashima, Noriko Odani-Kawabata, Naruhiro Ishida, Masatsugu Nakamura.   

Abstract

PURPOSE: The aim of this study was to evaluate and compare the effects of repeated administrations of three prostaglandin F(2alpha) analogs (tafluprost, latanoprost, and travoprost) on optic nerve head (ONH) blood flow in normal rabbits.
METHODS: Male Dutch rabbits were housed under a 12-h light-dark cycle for use in this study. A quantitative index of blood flow, the squared blur rate (SBR), was determined using laser speckle flowgraphy. Saline, 0.0015% tafluprost, 0.005% latanoprost, or 0.004% travoprost (each 50 microL) was topically administered into the left eye once daily for 28 days. ONH blood flow was measured before the start at the course of treatment (baseline), and on day 14 and/or day 28 [measurements being made at 0, 30, and/or 60 min after drugs application on day 14 and/or day 28]. Heart rate was also measured at these time points.
RESULTS: Tafluprost, latanoprost, and travoprost each increased the ONH blood flow at all measurement points on day 14 and/or day 28. The 0 min SBR value on day 14 was greater than the baseline SBR value by 8.7% + or - 4.4% for tafluprost and by 5.8% + or - 1.7% for latanoprost. The 0 min SBR value on day 28 was greater than the baseline SBR value by 11.9% + or - 3.9% for tafluprost, by 7.2% + or - 4.3% for latanoprost, and by 6.7% + or - 3.5% for travoprost. The increasing state of the ONH blood flow continued within 60 min after a topical administration of tafluprost, latanoprost, or travoprost. Tafluprost, latanoprost, and travoprost did not change heart rate (vs. the baseline value) at any measurement points.
CONCLUSIONS: Repeated topical administration of any of the three prostaglandin F(2alpha) analogs increased ONH blood flow in rabbits, without changing heart rate. The increase in ONH blood flow induced by tafluprost was greater than that induced by latanoprost (P = 0.086) or travoprost (P = 0.037) at 60 min on day 28.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334534     DOI: 10.1089/jop.2009.0100

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  15 in total

Review 1.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

Review 2.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

Review 3.  Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

Review 4.  Effects of Tafluprost on Ocular Blood Flow.

Authors:  Xinyue Zhang; Xiaoyu Zhou; Yang Zhao; Xiang Yang; Dengming Zhou; Baihua Chen; Xuanchu Duan
Journal:  Ophthalmol Ther       Date:  2022-09-15

5.  Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Dorota Pozarowska
Journal:  Clin Ophthalmol       Date:  2010-10-21

6.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

Review 7.  Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

8.  Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.

Authors:  Yang Liu; Weiming Mao
Journal:  Clin Ophthalmol       Date:  2012-12-21

9.  Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.

Authors:  Sıtkı Samet Ermiş
Journal:  Clin Ophthalmol       Date:  2012-05-07

10.  A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.

Authors:  Françoise Brignole-Baudouin; Nicolas Desbenoit; Gregory Hamm; Hong Liang; Jean-Pierre Both; Alain Brunelle; Isabelle Fournier; Vincent Guerineau; Raphael Legouffe; Jonathan Stauber; David Touboul; Maxence Wisztorski; Michel Salzet; Olivier Laprevote; Christophe Baudouin
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.